Government Relations and Policy

Recent Activity

ARM Statement in Response to U.S. Senator Kirk's REGROW Act - March/April 2016:

The Alliance for Regenerative Medicine is appreciative of Senator Kirk’s longtime support of the regenerative medicine sector and his belief in the transformative durable treatments and potential cures this field holds for patients. Our organization is committed to our continued cooperation with Senator Kirk and his staff to advance policies supportive of this sector and expediting potentially life-saving cell therapies, gene therapies and other regenerative medicine products.

However, ARM cannot support the REGROW Act. We continue to believe the proposal does not contain critical statutory protections for patients.  We look forward to a continuing dialogue with the sponsors of REGROW Act as well as other stakeholders to create alternative approaches to ensure access to safe and effective regenerative medicine therapies without putting patients at risk, disadvantaging American therapeutic developers and potentially damaging a very promising field of medicine.

ARM's letter to Senator Mark Kirk's office, March 31, 2016

Appendix to letter, March 31, 2016

******

 

Medical Technology Caucus Briefing - November 12, 2014

Senators ask for GAO Study on Regenerative Medicine

ARM Statement Regarding Potential Budget Cuts to the FDA and NIH

UK House of Lords Submission

Sweeping FDA Reforms Successfully Enacted

Policy and Legislation Overview

Regenerative Medicine Promotion Act

Major provisions of the bill include: 

  • requiring that the U.S. Government Accountability Office (USGAO) be responsible for strategic assessment of all federal agency activities related to regenerative medicine
  • creating a multi-agency Regenerative Medicine Coordinating Council within the Department of Health and Human Services (HHS)
  • establishing grant programs to accelerate the availability of life-saving regenerative medicine therapies and research tools
  • funding of critical regulatory research at the FDA.

Human Embryonic Stem Cell Research Update

Regenerative medicine achieved a major milestone concerning federal funding of human embryonic stem cell (hESC) research when, in the spring of 2011, the U.S. Court of Appeals overturned an August 2010 preliminary injunction that, by a vote of 2-1, prohibited the federal government from funding research involving human embryonic stem cells. The court held that funding such research is not prohibited by a statute (known as the Dickey-Wicker Amendment) that prohibits federal funding of “research in which a human embryo or embryos are destroyed.” The court also held—contrary to the lower court—that enjoining hESC research would cause harm to the government significantly greater than the harm that the plaintiffs would suffer without an injunction. Thus, since that time, the NIH developed funding guidelines for researcher-grantees.

National Institute for Standards and Technology (NIST)

Supporting increased funding for the National Institute for Standards and Technology (NIST) regenerative medicine programs and the FDA are also legislative priorities for the Alliance. Positive news occurred in July 2011, when the House encouraged NIST to consider supporting standards and measurement work in regenerative medicine technologies under the Scientific and Technical Research and Services budget, which was increased by $10 million from 2011 to 2012. Additionally, the FDA received a $50 million budget increase in FY 2012.

National Institutes of Health Appoints Dr. Mahendra Rao

In August 2011 the National Institutes of Health appointed the esteemed human embryonic stem cell scientist Dr. Mahendra Rao as Director of the new Intramural Center for Regenerative Medicine (NIH-CRM). The NIH-CRM is an initiative to create a world-class center of excellence in stem cell technology on the NIH campus. Research at NIH-CRM will include induced pluripotent stem cells (iPSC), which have potential applications in many systems and organs of the body. A major goal for the center is to build upon existing NIH investments in stem cell research to advance translational studies and, ultimately, cell-based therapies in the NIH Clinical Center. The center will also serve as a resource for the scientific community, providing stem cells, as well as the supporting protocols and standard operating procedures used to derive culture and differentiate them into different cell types for research and potential regenerative therapies.